InventisBio Co., Ltd. (China)

Alternate names: InventisBio, InventisBio Co., Limited, InventisBio Co., Ltd., InventisBio Inc.

ROR: 05s4wn714

OpenAlex ID: I4405268094

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

2023 · Ziming Li, Zhengbo Song, et al. · Journal of Thoracic Oncology · 92

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial

2024 · Ziming Li, Xiaomin Dang, et al. · The Lancet Respiratory Medicine · 55

D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity

2023 · Zhe Shi, Jifang Weng, et al. · Cancer Science · 43

PDF

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

2025 · Dan-Yun Ruan, Hao-Xiang Wu, et al. · Signal Transduction and Targeted Therapy · 31

PDF

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

2022 · Shun Lu, Yiping Zhang, et al. · Journal of Thoracic Oncology · 29

PDF

Abstract 932: Discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models

2021 · Zhe Shi, Jifang Weng, et al. · Cancer Research · 28

550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study

2023 · R-H. Xu, Y. Xu, et al. · Annals of Oncology · 16

PDF

Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer

2022 · Hong Jian, Kai Wang, et al. · The Oncologist · 14

PDF

Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.

2023 · Dan-yun Ruan, Myung Ah Lee, et al. · Journal of Clinical Oncology · 13

PDF

Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models

2018 · Yaolin Wang, Zhe Shi, et al. · Cancer Research · 9

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer

2025 · Noboru Yamamoto, Dong Yan, et al. · British Journal of Cancer · 7

1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)

2023 · S. Kondo, D. Yan, et al. · Annals of Oncology · 6

PDF

Abstract 1056: Potent in vivo anti-tumor activity of D-1553 as a single agent and in combination with targeted therapeutics in a broad spectrum of patient-derived xenograft tumor models with KRas G12C mutation

2021 · Zhe Shi, Jifang Weng, et al. · Cancer Research · 6

Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study

2025 · Zhengbo Song, Ziming Li, et al. · European Journal of Cancer · 5

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

2024 · Shun Lu, Yiping Zhang, et al. · Lung Cancer · 5

Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

2024 · Ziming Li, Xiaomin Dang, et al. · Cancer Research · 5

OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial

2022 · S. Lu, H. Jian, et al. · Journal of Thoracic Oncology · 5

PDF

Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial

2025 · Jianzhong Zhang, Cheng Zhou, et al. · Journal of the American Academy of Dermatology · 4

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation

2022 · Timothy Price, Jaspreet Grewal, et al. · Cancer Research · 4

Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial

2026 · Zhengbo Song, Xingya Li, et al. · The Lancet Respiratory Medicine · 3

Op0205 Phase I Study of D-0120, a Novel Urat1 Inhibitor in Clinical Development for Hyperuricemia and Gout

2020 · L. Zhang, D. Wyatt, et al. · Annals of the Rheumatic Diseases · 3

PDF

Abstract PS15-02: A Phase Ⅰb Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage

2024 · Jiayu Wang, Tao Sun, et al. · Cancer Research · 2

Abstract 2736: Preclinical pharmacologic and pharmacodynamic studies of a novel and potent IDO1 inhibitor D-0751

2018 · Yaolin Wang, Zhe Shi, et al. · Cancer Research · 2

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study

2026 · Meng Wang, Quanying Zhang, et al. · Clinical and Translational Science · 1

PDF

Abstract LB188: YF550 is a potent and selective inhibitor of KIF18A, specifically targeting CIN+ cancer cells

2025 · Yaolin Wang, Rongfeng Liu, et al. · Cancer Research · 1

Works count: 36

Citation count: 2,468